Bayer: Nexavar study shows survival boost

Bayer and Onyx Pharmaceuticals are anticipating the release of two new studies of their liver cancer treatment Nexavar; the studies include evidence of extended survival in more than 40 percent of patients and identification of biomarkers that might predict success with Nexavar therapy. Release